YMAB vs. AVDL, COGT, OCS, CDMO, QURE, PRAX, AVXL, XERS, CMRX, and ABCL
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Oculis (OCS), Avid Bioservices (CDMO), uniQure (QURE), Praxis Precision Medicines (PRAX), Anavex Life Sciences (AVXL), Xeris Biopharma (XERS), Chimerix (CMRX), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.
Y-mAbs Therapeutics vs.
Y-mAbs Therapeutics (NASDAQ:YMAB) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
In the previous week, Y-mAbs Therapeutics had 4 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 8 mentions for Y-mAbs Therapeutics and 4 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 0.85 beat Y-mAbs Therapeutics' score of 0.23 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media.
Y-mAbs Therapeutics currently has a consensus target price of $18.30, suggesting a potential upside of 268.95%. Avadel Pharmaceuticals has a consensus target price of $19.88, suggesting a potential upside of 144.77%. Given Y-mAbs Therapeutics' higher probable upside, research analysts plainly believe Y-mAbs Therapeutics is more favorable than Avadel Pharmaceuticals.
Avadel Pharmaceuticals received 211 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 66.48% of users gave Avadel Pharmaceuticals an outperform vote while only 63.30% of users gave Y-mAbs Therapeutics an outperform vote.
Y-mAbs Therapeutics has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.
70.8% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 22.5% of Y-mAbs Therapeutics shares are held by company insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Y-mAbs Therapeutics has a net margin of -28.22% compared to Avadel Pharmaceuticals' net margin of -52.53%. Y-mAbs Therapeutics' return on equity of -24.61% beat Avadel Pharmaceuticals' return on equity.
Y-mAbs Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Summary
Y-mAbs Therapeutics beats Avadel Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:YMAB) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy YMAB Stock Free YMAB Stock Alerts